Eli Lilly (LLY) to acquire Ajax Therapeutics for up to USD 2.3bln in cash, and is to advance outcomes for patients with myelofibrosis and polycythemia vera

Eli Lilly's acquisition of Ajax Therapeutics for up to $2.3 billion underscores its strategic push into hematological conditions, notably myelofibrosis and polycythemia vera.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Alibaba (BABA) launches limited beta of Happyhorse 1.0 video model

Verizon Communications (VZ) Q1 2026 (USD): Adj. EPS 1.28 (exp. 1.21), Revenue 34.4bln (exp. 34.82bln), Adj. EBITDA 13.4bln (exp. 13.14bln)

Eli Lilly (LLY) to acquire Ajax Therapeutics for up to USD 2.3bln in cash, and is to advance outcomes for patients with myelofibrosis and polycythemia vera

JPMorgan (JPM) is said to be moving a number of positions to London from Paris, Bloomberg reports citing sources.

Chinese Finance Ministry says it appreciates Moody's upgrade of China's outlook; will continue to promote the transformation of economic structure

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal not only suggests confidence in the future of these therapies but could also influence investor sentiment in the pharmaceuticals sector as it signals a proactive stance in expanding their therapeutic portfolio, potentially impacting stock valuations and market dynamics in related sectors.

Related headlines

The whole workspace, free to try.

Try it free